Vadodara drug maker, dating to 1907, with three API plants and six formulation plants. Holds US DMFs for 6 peptide APIs, including glatiramer and tirzepatide.
- Model
- Manufacturer
- Manufacturer?
- Yes
Glatiramer is a random peptide polymer used in multiple sclerosis (Copaxone).
6 listed companies hold an active US Type II Drug Master File for Glatiramer API, based in India (3), United States (2), China (1). 5 have a regulator record of GMP manufacturing.
Ordered by score. Scores follow the published rules and are not affected by paid placement. Updated 2026-11-13.
Source: FDA Drug Master File list. Holding a DMF is a regulatory filing, not an FDA approval.
Vadodara drug maker, dating to 1907, with three API plants and six formulation plants. Holds US DMFs for 6 peptide APIs, including glatiramer and tirzepatide.
Peptide API subsidiary of Aurobindo Pharma with a plant near Hyderabad. Makes generic peptide APIs and runs GMP contract projects from mg to kg scale.
Hyderabad injectables CDMO founded 1978, promoted by Fosun Pharma; FDA-inspected sites; US DMF for glatiramer acetate.
US peptide API CDMO with facilities in the US and China.
Chinese peptide drug manufacturer producing APIs and finished products.
US generics, specialty and biosimilars company with operations in the US, India and Ireland; US DMF for glatiramer acetate.
Companies holding active US DMFs for Glatiramer include Alembic Pharmaceuticals Ltd, Auro Peptides Ltd, Gland Pharma Ltd, AmbioPharm, Hybio Pharmaceutical and Amneal Pharmaceuticals LLC. Other manufacturers may supply it without a US DMF.
Among listed DMF holders: India (3), United States (2), China (1).
No. FDA reviews a DMF when a drug application references it and does not approve DMFs on their own.